Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: Two case reports

Journal of Medical Case Reports

Volumn 8, Issue 1, 2014, Pages

  Carls, Alexandra ^a   Winter, Julia ^a   Enderle, Yeliz ^a   Burhenne, Jürgen ^a   Gorenflo, Matthias ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Enteral; Plasma concentration; Pulmonary hypertension; Sildenafil; Sublingual

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; AMBRISENTAN; CASPOFUNGIN; CEFTAZIDIME; CHLORAL HYDRATE; CLONIDINE; COLECALCIFEROL; DOBUTAMINE; DRUG METABOLITE; ETACRYNIC ACID; ETIRACETAM; FUROSEMIDE; LEVOTHYROXINE; LISINOPRIL; METILDIGOXIN; MIDAZOLAM; MILRINONE; N DESMETHYL SILDENAFIL; NEOSTIGMINE; NITRIC OXIDE; OMEPRAZOLE; OXYGEN; PARACETAMOL; PHENOBARBITAL; SILDENAFIL; SIMETHICONE; SODIUM FLUORIDE; TEICOPLANIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; AORTA COARCTATION; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; CASE REPORT; CAUCASIAN; CHILD; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; ECHOCARDIOGRAPHY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MITRAL VALVE REGURGITATION; NASOGASTRIC TUBE; NEWBORN; PATENT DUCTUS ARTERIOSUS; PATENT FORAMEN OVALE; PERSISTENT LEFT SUPERIOR VENA CAVA; POSITIVE END EXPIRATORY PRESSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; BIOAVAILABILITY; COMPLICATION; CONGENITAL HEART MALFORMATION; HYPERTENSION, PULMONARY; METABOLISM; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; BIOLOGICAL AVAILABILITY; CHILD, PRESCHOOL; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; MALE; PIPERAZINES; PURINES; SULFONES; VASODILATOR AGENTS;

EID: 84903821169     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-8-171     Document Type: Article

References (20)

1. Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Wardle AJ, Tulloh RM, Arch Dis Child Educ Pract Ed 2013 98 141 147 10.1136/archdischild-2013-303981 23771819
2. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Nichols DJ, Muirhead GJ, Harness JA, Br J Clin Pharmacol 2002 53 Suppl 1 5S 12S 11879254
3. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Ahsman MJ, Witjes BC, Wildschut ED, Sluiter I, Vulto AG, Tibboel D, Mathot RA, Arch Dis Child Fetal Neonatal Ed 2010 95 109 F114 10.1136/adc.2009.168336 19949232
4. Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN, J Am Coll Cardiol 2010 55 1456 1462 10.1016/j.jacc.2009.11.065 20359596
5. Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. Lammers AE, Haworth SG, Pierce CM, Cardiol Young 2006 16 84 86 10.1017/S1047951105002155 16454884 (Pubitemid 43203366)
6. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL, Intensive Care Med 2011 37 502 509 10.1007/s00134-010- 2065-4 21069290
7. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, Kuppe H, Kuebler WM, Circ Heart Fail 2011 4 198 206 10.1161/CIRCHEARTFAILURE.110.957050 21216837
8. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Nahata MC, Morosco RS, Brady MT, Am J Health Syst Pharm 2006 63 254 257 10.2146/ajhp050208 16434784 (Pubitemid 43165377)
9. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL, Circulation 2012 125 324 334 10.1161/CIRCULATIONAHA.110.016667 22128226
10. US Food and Drug Administration, FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension Silver Spring, MD: FDA 2012 Available at http://www.fda.gov/drugs/ drugsafety/ucm317123.htm (accessed 25 March 2014)
11. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B, Feinstein J, Fineman J, Raj U, Humpl T, Pediatric Pulmonary Hypertension Network (PPHNet), Am J Respir Crit Care Med 2013 187 572 575 10.1164/rccm.201210-1928PP 23220921
12. The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction. De Siati M, Saugo M, Franzolin N, Arch Ital Urol Androl 2003 75 18 20 12741340 (Pubitemid 36505768)
13. [Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure] [in English Portuguese and Spanish]. Freitas AF Jr, Bacal F, Oliveira JL Jr, Santos RHB, Moreira LFP, Silva CR, Mangini S, Carneiro RMD, Fiorelli AI, Bocchi EA, Arq Bras Cardiol 2009 92 116 126 19360244
14. An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. Zayed R, Kamel AO, Shukr M, El-Shamy A, Acta Pharm 2012 62 411 432 23470352
15. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N, Br J Clin Pharmacol 2000 50 99 107 10.1046/j.1365-2125.2000.00245.x 10930961 (Pubitemid 30612027)
16. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B, Br J Clin Pharmacol 2002 53 Suppl 1 21S 30S 11879256
17. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. de Wildt SN, Expert Opin Drug Metab Toxicol 2011 7 935 948 10.1517/17425255.2011.577739 21548840
18. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM, Clin Pharmacol Ther 2007 82 265 274 10.1038/sj.clpt.6100138 17344806 (Pubitemid 47258464)
19. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Hyland R, Roe EG, Jones BC, Smith DA, Br J Clin Pharmacol 2001 51 239 248 11298070 (Pubitemid 32391501)
20. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Karatza AA, Bush A, Magee AG, Int J Cardiol 2005 100 267 273 10.1016/j.ijcard.2004.09.002 15823634